Login|Register|Forget password|Dashboard Back to Home|Contact|Shopcart
Unverified1st Year

Hangzhou Excelente Chemicals Co., Ltd.  

Agriculture & Food,Chemicals,Health & Medicine

Search
新闻中心
  • 暂无新闻
产品分类
  • 暂无分类
联系方式
  • 联系人:Adams
  • 电话:86-571-62113188
  • 传真:86-571-62117288
站内搜索
 
荣誉资质
  • 暂未上传
友情链接
  • 暂无链接
首页 > Products > Bicalutamide USP Good Quality Competitive Price CAS No 90357-06-5
Bicalutamide USP Good Quality Competitive Price CAS No 90357-06-5
单价 $300.00 / kg对比
询价 暂无
浏览 155
发货 Chinazhejianghangzhou
库存 100kg
过期 长期有效
更新 2020-06-13 10:51
 
详细信息
Product Name: Bicalutamide USP Good Quality Competitive Price CAS No 90357-06-5 Model NO.: USP/BP Purity: >99% State: Solid Suitable for: Elderly, Children, Adult Certification: ISO 9001, USP Customized: Non-Customized Powder: Yes Trademark: Excelente Transport Package: 25kg/Drum Specification: USP Origin: Zhejiang HS Code: 2926909090 Product Description Product descriptionBicalutamide was launched in the United Kingdom, its first worldwide market, for the treatment of advanced prostate cancer in combination with an LHRH analog or surgical castration. Anon-steroidal, peripherally selective antiandrogen, bicalutamide inhibits the action of dihydrotestosterone and testosterone at target sites by competitive binding to the cytosolic androgen receptor. It was reportedly well tolerated with no significant cardiovascular and metabolic side effects due to the benefit of lacking any steroid activity. The efficacy of bicalutamide as amonotherapy has been demonstrated clinically. Promising response rates were also reported in treating colorectal, breast, pancreas and non-small cell lung cancers.ApplicationBicalutamid is used primarily in the treatment of early and advanced prostate cancer. It is approved at adosage of 50 mg/day as acombination therapy with agonadotropin-releasing hormone (GnRH) analogue or orchiectomy (that is, surgical or medical castration) in the treatment of stage D2 metastatic prostate cancer (mPC), and as amonotherapy at adosage of 150 mg/day for the treatment of stage Cor D1 locally advanced prostate cancer (LAPC). Although effective in mPC and LAPC, bicalutamid is no longer indicated for the treatment of localized prostate cancer (LPC) due to negative findings in the Early Prostate Cancer (EPC) trial.Package10kg/25kg drumSpecificationAnalysis ItemIndexesCharacteristicsWhiteto off-whitepowderSolubilityFreely soluble intetrahydrofuranand inacetone,soluble in acetonitrile, sparingly soluble in methanol, slightly soluble in alcohol.IdentificationInfrared spectrum:Infrared absorptionspectrohotmetry /confirm/iHPLC: The same spectrum corresponds to standardResidue on ignitionNMT 0.1%Heavy metalsNMT10ppmWaterNMT0.2%OrganicimpuritiesBicalutamide aminobenzonitrileNMT 0.1%Bicalutamide relate compound ANMT 0.1%Bicalutamide relate compoundBNMT 0.1%Desfluoro bicalutamideNMT 0.2%2-Fluoro bicalutamideNMT 0.2%DeoxybicalutamideNMT 0.2%Bicalutamide sulfideNMT 0.1%Any unspecified impurityNMT 0.1%Total impuritiesNMT 0.5%Assay 98.0~102.0%